Relationship between response rate and median survival in patients with advanced non-small cell lung cancer

Comparison of ONCONASE(®) with other anticancer agents

S. M. Mikulski, H. G. Chun, A. Mittelman, Timothy Panella, C. A. Puccio, K. Shogen, J. J. Costanzi

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

The role of systemic cytotoxic therapy for the treatment of advanced non-small cell lung cancer (NSCLC) remains controversial. The response rate (RR) and the median survival time (MST) are the two most frequently used parameters for the assessment of efficacy of the anticancer therapies. The relationship between the previously reported RRs and MSTs from published chemotherapy trials in patients with advanced NSCLC was examined using linear regression analysis. The MST of the thirty patients with advanced NSCLC treated with ONCONASE (ONC) as a single agent was 7.7 months which compared favorably with the MSTs of patients treated with a variety of chemotherapeutic regimens either as single agents or combinations, as well as placebo and supportive care only. Moreover, the toxicity profile of ONC compared favorably to the profiles of other chemotherapy regimens. ONC had a favorable impact on the overall MST, including patients with stage IV disease, patients with poor performance status, and patients previously treated with radiotherapy and chemotherapy. The MST of 5 patients who had a stabilization of previously progressive disease was 9.3 months. Based on its positive impact on the MST, ONC appears to have a single agent activity in patients with advanced NSCLC, and it should be further investigated, particularly in combination with synergistic drugs, in concurrently controlled and prospectively randomized clinical trials. The duration and the quality of survival should be considered as the most meaningful parameters in assessing clinical efficacy of anticancer agents.

Original languageEnglish (US)
Pages (from-to)889-897
Number of pages9
JournalInternational Journal of Oncology
Volume6
Issue number4
StatePublished - Mar 28 1995
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Antineoplastic Agents
Survival Rate
Survival
Drug Therapy
Linear Models
Radiotherapy
Therapeutics
Randomized Controlled Trials
Placebos
Regression Analysis
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Relationship between response rate and median survival in patients with advanced non-small cell lung cancer : Comparison of ONCONASE(®) with other anticancer agents. / Mikulski, S. M.; Chun, H. G.; Mittelman, A.; Panella, Timothy; Puccio, C. A.; Shogen, K.; Costanzi, J. J.

In: International Journal of Oncology, Vol. 6, No. 4, 28.03.1995, p. 889-897.

Research output: Contribution to journalArticle

@article{f689f33891d841d9ad2bcca2cbc85251,
title = "Relationship between response rate and median survival in patients with advanced non-small cell lung cancer: Comparison of ONCONASE({\circledR}) with other anticancer agents",
abstract = "The role of systemic cytotoxic therapy for the treatment of advanced non-small cell lung cancer (NSCLC) remains controversial. The response rate (RR) and the median survival time (MST) are the two most frequently used parameters for the assessment of efficacy of the anticancer therapies. The relationship between the previously reported RRs and MSTs from published chemotherapy trials in patients with advanced NSCLC was examined using linear regression analysis. The MST of the thirty patients with advanced NSCLC treated with ONCONASE (ONC) as a single agent was 7.7 months which compared favorably with the MSTs of patients treated with a variety of chemotherapeutic regimens either as single agents or combinations, as well as placebo and supportive care only. Moreover, the toxicity profile of ONC compared favorably to the profiles of other chemotherapy regimens. ONC had a favorable impact on the overall MST, including patients with stage IV disease, patients with poor performance status, and patients previously treated with radiotherapy and chemotherapy. The MST of 5 patients who had a stabilization of previously progressive disease was 9.3 months. Based on its positive impact on the MST, ONC appears to have a single agent activity in patients with advanced NSCLC, and it should be further investigated, particularly in combination with synergistic drugs, in concurrently controlled and prospectively randomized clinical trials. The duration and the quality of survival should be considered as the most meaningful parameters in assessing clinical efficacy of anticancer agents.",
author = "Mikulski, {S. M.} and Chun, {H. G.} and A. Mittelman and Timothy Panella and Puccio, {C. A.} and K. Shogen and Costanzi, {J. J.}",
year = "1995",
month = "3",
day = "28",
language = "English (US)",
volume = "6",
pages = "889--897",
journal = "International Journal of Oncology",
issn = "1019-6439",
publisher = "Spandidos Publications",
number = "4",

}

TY - JOUR

T1 - Relationship between response rate and median survival in patients with advanced non-small cell lung cancer

T2 - Comparison of ONCONASE(®) with other anticancer agents

AU - Mikulski, S. M.

AU - Chun, H. G.

AU - Mittelman, A.

AU - Panella, Timothy

AU - Puccio, C. A.

AU - Shogen, K.

AU - Costanzi, J. J.

PY - 1995/3/28

Y1 - 1995/3/28

N2 - The role of systemic cytotoxic therapy for the treatment of advanced non-small cell lung cancer (NSCLC) remains controversial. The response rate (RR) and the median survival time (MST) are the two most frequently used parameters for the assessment of efficacy of the anticancer therapies. The relationship between the previously reported RRs and MSTs from published chemotherapy trials in patients with advanced NSCLC was examined using linear regression analysis. The MST of the thirty patients with advanced NSCLC treated with ONCONASE (ONC) as a single agent was 7.7 months which compared favorably with the MSTs of patients treated with a variety of chemotherapeutic regimens either as single agents or combinations, as well as placebo and supportive care only. Moreover, the toxicity profile of ONC compared favorably to the profiles of other chemotherapy regimens. ONC had a favorable impact on the overall MST, including patients with stage IV disease, patients with poor performance status, and patients previously treated with radiotherapy and chemotherapy. The MST of 5 patients who had a stabilization of previously progressive disease was 9.3 months. Based on its positive impact on the MST, ONC appears to have a single agent activity in patients with advanced NSCLC, and it should be further investigated, particularly in combination with synergistic drugs, in concurrently controlled and prospectively randomized clinical trials. The duration and the quality of survival should be considered as the most meaningful parameters in assessing clinical efficacy of anticancer agents.

AB - The role of systemic cytotoxic therapy for the treatment of advanced non-small cell lung cancer (NSCLC) remains controversial. The response rate (RR) and the median survival time (MST) are the two most frequently used parameters for the assessment of efficacy of the anticancer therapies. The relationship between the previously reported RRs and MSTs from published chemotherapy trials in patients with advanced NSCLC was examined using linear regression analysis. The MST of the thirty patients with advanced NSCLC treated with ONCONASE (ONC) as a single agent was 7.7 months which compared favorably with the MSTs of patients treated with a variety of chemotherapeutic regimens either as single agents or combinations, as well as placebo and supportive care only. Moreover, the toxicity profile of ONC compared favorably to the profiles of other chemotherapy regimens. ONC had a favorable impact on the overall MST, including patients with stage IV disease, patients with poor performance status, and patients previously treated with radiotherapy and chemotherapy. The MST of 5 patients who had a stabilization of previously progressive disease was 9.3 months. Based on its positive impact on the MST, ONC appears to have a single agent activity in patients with advanced NSCLC, and it should be further investigated, particularly in combination with synergistic drugs, in concurrently controlled and prospectively randomized clinical trials. The duration and the quality of survival should be considered as the most meaningful parameters in assessing clinical efficacy of anticancer agents.

UR - http://www.scopus.com/inward/record.url?scp=0028952578&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028952578&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 889

EP - 897

JO - International Journal of Oncology

JF - International Journal of Oncology

SN - 1019-6439

IS - 4

ER -